ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000D56

Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease

Identifieur interne : 000D56 ( PascalFrancis/Corpus ); précédent : 000D55; suivant : 000D57

Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease

Auteurs : R. A. Hauser ; T. B. Freeman ; B. J. Snow ; M. Nauert ; L. Gauger ; J. H. Kordower ; C. W. Olanow

Source :

Archives of neurology : (Chicago) [ 0003-9942 ] ; 1999.

RBID : Pascal:99-0381130

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Stade avancé, Survie, Greffe, Bilatéral, Putamen, Locus niger, Neurone, Foetus, Dyskinésie, Tomoscintigraphie, Positon, Fluorodopa(18F), Protocole thérapeutique, Traitement, Long terme, Evolution, Adulte, Mâle, Femelle.

English descriptors

KwdEn :
- Adult, Advanced stage, Bilateral, Dyskinesia, Emission tomography, Evolution, Female, Fetus, Fluorodopa(18F), Graft, Locus niger, Long term, Male, Neuron, Parkinson disease, Positron, Putamen, Survival, Therapeutic protocol, Treatment.

Abstract

Background: Parkinson disease (PD) is associated with a progressive loss of nigrostriatal dopamine neurons. Medication therapy provides adequate control of symptoms for several years, but long-term treatment is complicated by progressive disability and the development of motor fluctuations and dyskinesias. In animal models of PD, fetal nigral transplants have been shown to survive grafting into the striatum, provide extensive striatal reinnervation, and improve motor function. In patients with PD, cell survival and clinical benefit have been observed following fetal nigral grafting, but results have been inconsistent. Objective: To evaluate the safety and efficacy of bilateral fetal nigral transplantation into the postcommissural putamen in patients with advanced PD complicated by motor fluctuations and dyskinesias. Patients and Methods: Six patients with advanced PD underwent bilateral fetal nigral transplantation. Each patient received solid grafts derived from donors aged 61/2 to 9 weeks after conception stereotactically implanted into the postcommissural putamen using 3 to 4 donors per side. Cyclosporine was administered for approximately 6 months to provide immune suppression.(...)

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0003-9942`
A02	`01`			`@0 ARNEAS`
A03		`1`		`@0 Arch. neurol. : (Chic.)`
A05				`@2 56`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease`
A11	`01`	`1`		`@1 HAUSER (R. A.)`
A11	`02`	`1`		`@1 FREEMAN (T. B.)`
A11	`03`	`1`		`@1 SNOW (B. J.)`
A11	`04`	`1`		`@1 NAUERT (M.)`
A11	`05`	`1`		`@1 GAUGER (L.)`
A11	`06`	`1`		`@1 KORDOWER (J. H.)`
A11	`07`	`1`		`@1 OLANOW (C. W.)`
A14	`01`			`@1 Department of Neurology, University of South Florida @2 Tampa @3 USA @Z 1 aut. @Z 5 aut.`
A14	`02`			`@1 Department of Pharmacology and Experimental Therapeutics, University of South Florida @2 Tampa @3 USA @Z 1 aut. @Z 2 aut.`
A14	`03`			`@1 Division of Neurosurgery, University of South Florida @2 Tampa @3 USA @Z 2 aut.`
A14	`04`			`@1 Division of Neurology, University of British Columbia, University Hospital @2 Vancouver @3 CAN @Z 3 aut.`
A14	`05`			`@1 Women's Center @2 Tampa Fla @3 USA @Z 4 aut.`
A14	`06`			`@1 Department of Neurological Sciences, Rush Presbyterian-St Lukes' Medical Center @2 Chicago Ill @3 USA @Z 6 aut.`
A14	`07`			`@1 Department of Neurology, Mount Sinai School of Medicine @2 New York, NY @3 USA @Z 7 aut.`
A20				`@1 179-187`
A21				`@1 1999`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 2048B @5 354000074327930050`
A44				`@0 0000 @1 © 1999 INIST-CNRS. All rights reserved.`
A45				`@0 33 ref.`
A47	`01`	`1`		`@0 99-0381130`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Archives of neurology : (Chicago)`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Background: Parkinson disease (PD) is associated with a progressive loss of nigrostriatal dopamine neurons. Medication therapy provides adequate control of symptoms for several years, but long-term treatment is complicated by progressive disability and the development of motor fluctuations and dyskinesias. In animal models of PD, fetal nigral transplants have been shown to survive grafting into the striatum, provide extensive striatal reinnervation, and improve motor function. In patients with PD, cell survival and clinical benefit have been observed following fetal nigral grafting, but results have been inconsistent. Objective: To evaluate the safety and efficacy of bilateral fetal nigral transplantation into the postcommissural putamen in patients with advanced PD complicated by motor fluctuations and dyskinesias. Patients and Methods: Six patients with advanced PD underwent bilateral fetal nigral transplantation. Each patient received solid grafts derived from donors aged 61/2 to 9 weeks after conception stereotactically implanted into the postcommissural putamen using 3 to 4 donors per side. Cyclosporine was administered for approximately 6 months to provide immune suppression.(...)
C02	`01`	`X`		`@0 002B25J01`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Stade avancé @5 02`
C03	`02`	`X`	`ENG`	`@0 Advanced stage @5 02`
C03	`02`	`X`	`SPA`	`@0 Estadio avanzado @5 02`
C03	`03`	`X`	`FRE`	`@0 Survie @5 03`
C03	`03`	`X`	`ENG`	`@0 Survival @5 03`
C03	`03`	`X`	`SPA`	`@0 Sobrevivencia @5 03`
C03	`04`	`X`	`FRE`	`@0 Greffe @5 04`
C03	`04`	`X`	`ENG`	`@0 Graft @5 04`
C03	`04`	`X`	`SPA`	`@0 Injerto @5 04`
C03	`05`	`X`	`FRE`	`@0 Bilatéral @5 05`
C03	`05`	`X`	`ENG`	`@0 Bilateral @5 05`
C03	`05`	`X`	`SPA`	`@0 Bilateral @5 05`
C03	`06`	`X`	`FRE`	`@0 Putamen @5 06`
C03	`06`	`X`	`ENG`	`@0 Putamen @5 06`
C03	`06`	`X`	`SPA`	`@0 Putamen @5 06`
C03	`07`	`X`	`FRE`	`@0 Locus niger @5 07`
C03	`07`	`X`	`ENG`	`@0 Locus niger @5 07`
C03	`07`	`X`	`SPA`	`@0 Locus níger @5 07`
C03	`08`	`X`	`FRE`	`@0 Neurone @5 08`
C03	`08`	`X`	`ENG`	`@0 Neuron @5 08`
C03	`08`	`X`	`SPA`	`@0 Neurona @5 08`
C03	`09`	`X`	`FRE`	`@0 Foetus @5 09`
C03	`09`	`X`	`ENG`	`@0 Fetus @5 09`
C03	`09`	`X`	`SPA`	`@0 Feto @5 09`
C03	`10`	`X`	`FRE`	`@0 Dyskinésie @5 10`
C03	`10`	`X`	`ENG`	`@0 Dyskinesia @5 10`
C03	`10`	`X`	`SPA`	`@0 Disquinesia @5 10`
C03	`11`	`X`	`FRE`	`@0 Tomoscintigraphie @5 13`
C03	`11`	`X`	`ENG`	`@0 Emission tomography @5 13`
C03	`11`	`X`	`SPA`	`@0 Tomocentelleografía @5 13`
C03	`12`	`X`	`FRE`	`@0 Positon @5 14`
C03	`12`	`X`	`ENG`	`@0 Positron @5 14`
C03	`12`	`X`	`SPA`	`@0 Positrón @5 14`
C03	`13`	`X`	`FRE`	`@0 Fluorodopa(18F) @2 NK @2 FR @5 15`
C03	`13`	`X`	`ENG`	`@0 Fluorodopa(18F) @2 NK @2 FR @5 15`
C03	`13`	`X`	`SPA`	`@0 Fluorodopa(18F) @2 NK @2 FR @5 15`
C03	`14`	`X`	`FRE`	`@0 Protocole thérapeutique @5 16`
C03	`14`	`X`	`ENG`	`@0 Therapeutic protocol @5 16`
C03	`14`	`X`	`SPA`	`@0 Protocolo terapéutico @5 16`
C03	`15`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`15`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`15`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`16`	`X`	`FRE`	`@0 Long terme @5 18`
C03	`16`	`X`	`ENG`	`@0 Long term @5 18`
C03	`16`	`X`	`SPA`	`@0 Largo plazo @5 18`
C03	`17`	`X`	`FRE`	`@0 Evolution @5 19`
C03	`17`	`X`	`ENG`	`@0 Evolution @5 19`
C03	`17`	`X`	`SPA`	`@0 Evolución @5 19`
C03	`18`	`X`	`FRE`	`@0 Adulte @5 20`
C03	`18`	`X`	`ENG`	`@0 Adult @5 20`
C03	`18`	`X`	`SPA`	`@0 Adulto @5 20`
C03	`19`	`X`	`FRE`	`@0 Mâle @5 21`
C03	`19`	`X`	`ENG`	`@0 Male @5 21`
C03	`19`	`X`	`SPA`	`@0 Macho @5 21`
C03	`20`	`X`	`FRE`	`@0 Femelle @5 22`
C03	`20`	`X`	`ENG`	`@0 Female @5 22`
C03	`20`	`X`	`SPA`	`@0 Hembra @5 22`
C07	`01`	`X`	`FRE`	`@0 Homme`
C07	`01`	`X`	`ENG`	`@0 Human`
C07	`01`	`X`	`SPA`	`@0 Hombre`
C07	`02`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`03`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`03`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`03`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`04`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`04`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`04`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`05`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`05`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`05`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`06`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`06`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`06`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`07`	`X`	`FRE`	`@0 Chirurgie @5 45`
C07	`07`	`X`	`ENG`	`@0 Surgery @5 45`
C07	`07`	`X`	`SPA`	`@0 Cirugía @5 45`
C07	`08`	`X`	`FRE`	`@0 Mouvement involontaire @5 61`
C07	`08`	`X`	`ENG`	`@0 Involuntary movement @5 61`
C07	`08`	`X`	`SPA`	`@0 Movimiento involuntario @5 61`
C07	`09`	`X`	`FRE`	`@0 Trouble neurologique @5 62`
C07	`09`	`X`	`ENG`	`@0 Neurological disorder @5 62`
C07	`09`	`X`	`SPA`	`@0 Trastorno neurológico @5 62`
C07	`10`	`X`	`FRE`	`@0 Exploration radioisotopique @5 69`
C07	`10`	`X`	`ENG`	`@0 Radionuclide study @5 69`
C07	`10`	`X`	`SPA`	`@0 Exploración radioisotópica @5 69`
N21				`@1 242`

Format Inist (serveur)

NO :	PASCAL 99-0381130 INIST
ET :	Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease
AU :	HAUSER (R. A.); FREEMAN (T. B.); SNOW (B. J.); NAUERT (M.); GAUGER (L.); KORDOWER (J. H.); OLANOW (C. W.)
AF :	Department of Neurology, University of South Florida/Tampa/Etats-Unis (1 aut., 5 aut.); Department of Pharmacology and Experimental Therapeutics, University of South Florida/Tampa/Etats-Unis (1 aut., 2 aut.); Division of Neurosurgery, University of South Florida/Tampa/Etats-Unis (2 aut.); Division of Neurology, University of British Columbia, University Hospital/Vancouver/Canada (3 aut.); Women's Center/Tampa Fla/Etats-Unis (4 aut.); Department of Neurological Sciences, Rush Presbyterian-St Lukes' Medical Center/Chicago Ill/Etats-Unis (6 aut.); Department of Neurology, Mount Sinai School of Medicine/New York, NY/Etats-Unis (7 aut.)
DT :	Publication en série; Niveau analytique
SO :	Archives of neurology : (Chicago); ISSN 0003-9942; Coden ARNEAS; Etats-Unis; Da. 1999; Vol. 56; No. 2; Pp. 179-187; Bibl. 33 ref.
LA :	Anglais
EA :	Background: Parkinson disease (PD) is associated with a progressive loss of nigrostriatal dopamine neurons. Medication therapy provides adequate control of symptoms for several years, but long-term treatment is complicated by progressive disability and the development of motor fluctuations and dyskinesias. In animal models of PD, fetal nigral transplants have been shown to survive grafting into the striatum, provide extensive striatal reinnervation, and improve motor function. In patients with PD, cell survival and clinical benefit have been observed following fetal nigral grafting, but results have been inconsistent. Objective: To evaluate the safety and efficacy of bilateral fetal nigral transplantation into the postcommissural putamen in patients with advanced PD complicated by motor fluctuations and dyskinesias. Patients and Methods: Six patients with advanced PD underwent bilateral fetal nigral transplantation. Each patient received solid grafts derived from donors aged 61/2 to 9 weeks after conception stereotactically implanted into the postcommissural putamen using 3 to 4 donors per side. Cyclosporine was administered for approximately 6 months to provide immune suppression.(...)
CC :	002B25J01
FD :	Parkinson maladie; Stade avancé; Survie; Greffe; Bilatéral; Putamen; Locus niger; Neurone; Foetus; Dyskinésie; Tomoscintigraphie; Positon; Fluorodopa(18F); Protocole thérapeutique; Traitement; Long terme; Evolution; Adulte; Mâle; Femelle
FG :	Homme; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Chirurgie; Mouvement involontaire; Trouble neurologique; Exploration radioisotopique
ED :	Parkinson disease; Advanced stage; Survival; Graft; Bilateral; Putamen; Locus niger; Neuron; Fetus; Dyskinesia; Emission tomography; Positron; Fluorodopa(18F); Therapeutic protocol; Treatment; Long term; Evolution; Adult; Male; Female
EG :	Human; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Surgery; Involuntary movement; Neurological disorder; Radionuclide study
SD :	Parkinson enfermedad; Estadio avanzado; Sobrevivencia; Injerto; Bilateral; Putamen; Locus níger; Neurona; Feto; Disquinesia; Tomocentelleografía; Positrón; Fluorodopa(18F); Protocolo terapéutico; Tratamiento; Largo plazo; Evolución; Adulto; Macho; Hembra
LO :	INIST-2048B.354000074327930050
ID :	99-0381130

Links to Exploration step

Pascal:99-0381130

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease</title>
<author><name sortKey="Hauser, R A" sort="Hauser, R A" uniqKey="Hauser R" first="R. A." last="Hauser">R. A. Hauser</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of South Florida</s1>
<s2>Tampa</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Pharmacology and Experimental Therapeutics, University of South Florida</s1>
<s2>Tampa</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Freeman, T B" sort="Freeman, T B" uniqKey="Freeman T" first="T. B." last="Freeman">T. B. Freeman</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Pharmacology and Experimental Therapeutics, University of South Florida</s1>
<s2>Tampa</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Division of Neurosurgery, University of South Florida</s1>
<s2>Tampa</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Snow, B J" sort="Snow, B J" uniqKey="Snow B" first="B. J." last="Snow">B. J. Snow</name>
<affiliation><inist:fA14 i1="04"><s1>Division of Neurology, University of British Columbia, University Hospital</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nauert, M" sort="Nauert, M" uniqKey="Nauert M" first="M." last="Nauert">M. Nauert</name>
<affiliation><inist:fA14 i1="05"><s1>Women's Center</s1>
<s2>Tampa Fla</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gauger, L" sort="Gauger, L" uniqKey="Gauger L" first="L." last="Gauger">L. Gauger</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of South Florida</s1>
<s2>Tampa</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kordower, J H" sort="Kordower, J H" uniqKey="Kordower J" first="J. H." last="Kordower">J. H. Kordower</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Neurological Sciences, Rush Presbyterian-St Lukes' Medical Center</s1>
<s2>Chicago Ill</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Olanow, C W" sort="Olanow, C W" uniqKey="Olanow C" first="C. W." last="Olanow">C. W. Olanow</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Neurology, Mount Sinai School of Medicine</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">99-0381130</idno>
<date when="1999">1999</date>
<idno type="stanalyst">PASCAL 99-0381130 INIST</idno>
<idno type="RBID">Pascal:99-0381130</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000D56</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease</title>
<author><name sortKey="Hauser, R A" sort="Hauser, R A" uniqKey="Hauser R" first="R. A." last="Hauser">R. A. Hauser</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of South Florida</s1>
<s2>Tampa</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Pharmacology and Experimental Therapeutics, University of South Florida</s1>
<s2>Tampa</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Freeman, T B" sort="Freeman, T B" uniqKey="Freeman T" first="T. B." last="Freeman">T. B. Freeman</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Pharmacology and Experimental Therapeutics, University of South Florida</s1>
<s2>Tampa</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Division of Neurosurgery, University of South Florida</s1>
<s2>Tampa</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Snow, B J" sort="Snow, B J" uniqKey="Snow B" first="B. J." last="Snow">B. J. Snow</name>
<affiliation><inist:fA14 i1="04"><s1>Division of Neurology, University of British Columbia, University Hospital</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nauert, M" sort="Nauert, M" uniqKey="Nauert M" first="M." last="Nauert">M. Nauert</name>
<affiliation><inist:fA14 i1="05"><s1>Women's Center</s1>
<s2>Tampa Fla</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gauger, L" sort="Gauger, L" uniqKey="Gauger L" first="L." last="Gauger">L. Gauger</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of South Florida</s1>
<s2>Tampa</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kordower, J H" sort="Kordower, J H" uniqKey="Kordower J" first="J. H." last="Kordower">J. H. Kordower</name>
<affiliation><inist:fA14 i1="06"><s1>Department of Neurological Sciences, Rush Presbyterian-St Lukes' Medical Center</s1>
<s2>Chicago Ill</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Olanow, C W" sort="Olanow, C W" uniqKey="Olanow C" first="C. W." last="Olanow">C. W. Olanow</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Neurology, Mount Sinai School of Medicine</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Archives of neurology : (Chicago)</title>
<title level="j" type="abbreviated">Arch. neurol. : (Chic.)</title>
<idno type="ISSN">0003-9942</idno>
<imprint><date when="1999">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Archives of neurology : (Chicago)</title>
<title level="j" type="abbreviated">Arch. neurol. : (Chic.)</title>
<idno type="ISSN">0003-9942</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Advanced stage</term>
<term>Bilateral</term>
<term>Dyskinesia</term>
<term>Emission tomography</term>
<term>Evolution</term>
<term>Female</term>
<term>Fetus</term>
<term>Fluorodopa(18F)</term>
<term>Graft</term>
<term>Locus niger</term>
<term>Long term</term>
<term>Male</term>
<term>Neuron</term>
<term>Parkinson disease</term>
<term>Positron</term>
<term>Putamen</term>
<term>Survival</term>
<term>Therapeutic protocol</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Stade avancé</term>
<term>Survie</term>
<term>Greffe</term>
<term>Bilatéral</term>
<term>Putamen</term>
<term>Locus niger</term>
<term>Neurone</term>
<term>Foetus</term>
<term>Dyskinésie</term>
<term>Tomoscintigraphie</term>
<term>Positon</term>
<term>Fluorodopa(18F)</term>
<term>Protocole thérapeutique</term>
<term>Traitement</term>
<term>Long terme</term>
<term>Evolution</term>
<term>Adulte</term>
<term>Mâle</term>
<term>Femelle</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Parkinson disease (PD) is associated with a progressive loss of nigrostriatal dopamine neurons. Medication therapy provides adequate control of symptoms for several years, but long-term treatment is complicated by progressive disability and the development of motor fluctuations and dyskinesias. In animal models of PD, fetal nigral transplants have been shown to survive grafting into the striatum, provide extensive striatal reinnervation, and improve motor function. In patients with PD, cell survival and clinical benefit have been observed following fetal nigral grafting, but results have been inconsistent. Objective: To evaluate the safety and efficacy of bilateral fetal nigral transplantation into the postcommissural putamen in patients with advanced PD complicated by motor fluctuations and dyskinesias. Patients and Methods: Six patients with advanced PD underwent bilateral fetal nigral transplantation. Each patient received solid grafts derived from donors aged 61/2 to 9 weeks after conception stereotactically implanted into the postcommissural putamen using 3 to 4 donors per side. Cyclosporine was administered for approximately 6 months to provide immune suppression.(...)</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0003-9942</s0>
</fA01>
<fA02 i1="01"><s0>ARNEAS</s0>
</fA02>
<fA03 i2="1"><s0>Arch. neurol. : (Chic.)</s0>
</fA03>
<fA05><s2>56</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>HAUSER (R. A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>FREEMAN (T. B.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>SNOW (B. J.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>NAUERT (M.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>GAUGER (L.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>KORDOWER (J. H.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>OLANOW (C. W.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, University of South Florida</s1>
<s2>Tampa</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Pharmacology and Experimental Therapeutics, University of South Florida</s1>
<s2>Tampa</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Division of Neurosurgery, University of South Florida</s1>
<s2>Tampa</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Division of Neurology, University of British Columbia, University Hospital</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Women's Center</s1>
<s2>Tampa Fla</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Neurological Sciences, Rush Presbyterian-St Lukes' Medical Center</s1>
<s2>Chicago Ill</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Neurology, Mount Sinai School of Medicine</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>179-187</s1>
</fA20>
<fA21><s1>1999</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>2048B</s2>
<s5>354000074327930050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1999 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>33 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>99-0381130</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Archives of neurology : (Chicago)</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: Parkinson disease (PD) is associated with a progressive loss of nigrostriatal dopamine neurons. Medication therapy provides adequate control of symptoms for several years, but long-term treatment is complicated by progressive disability and the development of motor fluctuations and dyskinesias. In animal models of PD, fetal nigral transplants have been shown to survive grafting into the striatum, provide extensive striatal reinnervation, and improve motor function. In patients with PD, cell survival and clinical benefit have been observed following fetal nigral grafting, but results have been inconsistent. Objective: To evaluate the safety and efficacy of bilateral fetal nigral transplantation into the postcommissural putamen in patients with advanced PD complicated by motor fluctuations and dyskinesias. Patients and Methods: Six patients with advanced PD underwent bilateral fetal nigral transplantation. Each patient received solid grafts derived from donors aged 61/2 to 9 weeks after conception stereotactically implanted into the postcommissural putamen using 3 to 4 donors per side. Cyclosporine was administered for approximately 6 months to provide immune suppression.(...)</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B25J01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Stade avancé</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Advanced stage</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Estadio avanzado</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Survie</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Survival</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Sobrevivencia</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Greffe</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Graft</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Injerto</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Bilatéral</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Bilateral</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Bilateral</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Putamen</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Putamen</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Putamen</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Locus niger</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Locus niger</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Locus níger</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Neurone</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Neuron</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Neurona</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Foetus</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Fetus</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Feto</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Tomoscintigraphie</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Emission tomography</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Tomocentelleografía</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Positon</s0>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Positron</s0>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Positrón</s0>
<s5>14</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Fluorodopa(18F)</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>15</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Fluorodopa(18F)</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>15</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Fluorodopa(18F)</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>15</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Protocole thérapeutique</s0>
<s5>16</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Therapeutic protocol</s0>
<s5>16</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Protocolo terapéutico</s0>
<s5>16</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Long terme</s0>
<s5>18</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Long term</s0>
<s5>18</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Largo plazo</s0>
<s5>18</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Evolution</s0>
<s5>19</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Evolution</s0>
<s5>19</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Evolución</s0>
<s5>19</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Adulte</s0>
<s5>20</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Adult</s0>
<s5>20</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Adulto</s0>
<s5>20</s5>
</fC03>
<fC03 i1="19" i2="X" l="FRE"><s0>Mâle</s0>
<s5>21</s5>
</fC03>
<fC03 i1="19" i2="X" l="ENG"><s0>Male</s0>
<s5>21</s5>
</fC03>
<fC03 i1="19" i2="X" l="SPA"><s0>Macho</s0>
<s5>21</s5>
</fC03>
<fC03 i1="20" i2="X" l="FRE"><s0>Femelle</s0>
<s5>22</s5>
</fC03>
<fC03 i1="20" i2="X" l="ENG"><s0>Female</s0>
<s5>22</s5>
</fC03>
<fC03 i1="20" i2="X" l="SPA"><s0>Hembra</s0>
<s5>22</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Chirurgie</s0>
<s5>45</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Surgery</s0>
<s5>45</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Cirugía</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>61</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>61</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>61</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>62</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>62</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>62</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Exploration radioisotopique</s0>
<s5>69</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Radionuclide study</s0>
<s5>69</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Exploración radioisotópica</s0>
<s5>69</s5>
</fC07>
<fN21><s1>242</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 99-0381130 INIST</NO>
<ET>Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease</ET>
<AU>HAUSER (R. A.); FREEMAN (T. B.); SNOW (B. J.); NAUERT (M.); GAUGER (L.); KORDOWER (J. H.); OLANOW (C. W.)</AU>
<AF>Department of Neurology, University of South Florida/Tampa/Etats-Unis (1 aut., 5 aut.); Department of Pharmacology and Experimental Therapeutics, University of South Florida/Tampa/Etats-Unis (1 aut., 2 aut.); Division of Neurosurgery, University of South Florida/Tampa/Etats-Unis (2 aut.); Division of Neurology, University of British Columbia, University Hospital/Vancouver/Canada (3 aut.); Women's Center/Tampa Fla/Etats-Unis (4 aut.); Department of Neurological Sciences, Rush Presbyterian-St Lukes' Medical Center/Chicago Ill/Etats-Unis (6 aut.); Department of Neurology, Mount Sinai School of Medicine/New York, NY/Etats-Unis (7 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Archives of neurology : (Chicago); ISSN 0003-9942; Coden ARNEAS; Etats-Unis; Da. 1999; Vol. 56; No. 2; Pp. 179-187; Bibl. 33 ref.</SO>
<LA>Anglais</LA>
<EA>Background: Parkinson disease (PD) is associated with a progressive loss of nigrostriatal dopamine neurons. Medication therapy provides adequate control of symptoms for several years, but long-term treatment is complicated by progressive disability and the development of motor fluctuations and dyskinesias. In animal models of PD, fetal nigral transplants have been shown to survive grafting into the striatum, provide extensive striatal reinnervation, and improve motor function. In patients with PD, cell survival and clinical benefit have been observed following fetal nigral grafting, but results have been inconsistent. Objective: To evaluate the safety and efficacy of bilateral fetal nigral transplantation into the postcommissural putamen in patients with advanced PD complicated by motor fluctuations and dyskinesias. Patients and Methods: Six patients with advanced PD underwent bilateral fetal nigral transplantation. Each patient received solid grafts derived from donors aged 61/2 to 9 weeks after conception stereotactically implanted into the postcommissural putamen using 3 to 4 donors per side. Cyclosporine was administered for approximately 6 months to provide immune suppression.(...)</EA>
<CC>002B25J01</CC>
<FD>Parkinson maladie; Stade avancé; Survie; Greffe; Bilatéral; Putamen; Locus niger; Neurone; Foetus; Dyskinésie; Tomoscintigraphie; Positon; Fluorodopa(18F); Protocole thérapeutique; Traitement; Long terme; Evolution; Adulte; Mâle; Femelle</FD>
<FG>Homme; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Chirurgie; Mouvement involontaire; Trouble neurologique; Exploration radioisotopique</FG>
<ED>Parkinson disease; Advanced stage; Survival; Graft; Bilateral; Putamen; Locus niger; Neuron; Fetus; Dyskinesia; Emission tomography; Positron; Fluorodopa(18F); Therapeutic protocol; Treatment; Long term; Evolution; Adult; Male; Female</ED>
<EG>Human; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Surgery; Involuntary movement; Neurological disorder; Radionuclide study</EG>
<SD>Parkinson enfermedad; Estadio avanzado; Sobrevivencia; Injerto; Bilateral; Putamen; Locus níger; Neurona; Feto; Disquinesia; Tomocentelleografía; Positrón; Fluorodopa(18F); Protocolo terapéutico; Tratamiento; Largo plazo; Evolución; Adulto; Macho; Hembra</SD>
<LO>INIST-2048B.354000074327930050</LO>
<ID>99-0381130</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D56 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000D56 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:99-0381130
   |texte=   Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease

Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri